Stocktoria

Cresco Labs Inc. CRLBF

OTC · stock · Medicinal Chemicals & Botanical Products · website · IPO 2018-12-03 · LEI

Cresco Labs Inc. financials (annual)

Revenue
$770.9M $724.3M $655.8M 202320242025
Net income
-$175.5M -$74.4M -$135.4M 202320242025
Free cash flow
$3.2M $113.0M $37.8M 202320242025

Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023
Revenue$655.8M$724.3M$770.9M
Gross profit$324.6M$364.5M$362.4M
SG&A expense$247.5M$254.8M$299.2M
Operating income-$28.0M$107.3M-$87.8M
Income tax$44.6M$49.9M$33.0M
Net income-$135.4M-$74.4M-$175.5M
EPS (diluted)$-0.38$-0.22$-0.54
Operating cash flow$72.9M$132.5M$58.6M
Free cash flow$37.8M$113.0M$3.2M
Cash & equivalents$57.9M$137.6M$103.4M
Inventory$98.7M$83.3M$107.8M
Total assets$1.2B$1.4B$1.4B
Total liabilities$944.8M$967.2M$930.4M
Shareholders' equity$340.4M$474.9M$505.7M

Growth · year-over-year · Revenue CAGR -7.8%

MetricFY2025FY2024FY2023
Revenue growth-9.5%-6.0%
Free cash flow growth-66.6%+3454.2%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.